BioPharmSignal logoBioPharmSignal

Biotech News

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion Therapeutics (ESPR)Esperion TherapeuticsFDA / regulatory

– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (the

Related news

ESPREsperion Therapeutics2026-03-03 11:00 EST

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

View all latest news

Esperion Therapeutics

Oral Cardiometabolic Medicines Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase. Bempedoic Acid Franchise NEXLETOL and NEXLIZET are once-daily, non-statin...

Recent company news

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-05-14 20:30 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-05-13 12:00 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

ESPREsperion Therapeutics2026-05-01 11:00 EST

Esperion to be Acquired by ARCHIMED

ESPREsperion Therapeutics2026-04-23 12:00 EST

Esperion to Report First Quarter 2026 Financial Results on May 7

Stock data

Close
3.18 USD
Market cap
808.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States